Cephalon to Hold Conference Call with Investors Today at 5:30 p.m. EDT
FRAZER, Pa., May 6 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq:
CEPH) announced today that a Joint Advisory Committee to the U.S. Food and
Drug Administration (FDA) voted not to recommend approval of an expanded
label for FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of
breakthrough pain in opioid-tolerant patients with chronic pain conditions.
The panel expressed concerns about minimizing risks potentially associated
with an expanded indication of FENTORA. During the meeting, the company
presented a comprehensive and novel Risk Minimization Action Plan (RiskMAP)
to address these risks.
FDA action on the FENTORA supplemental new drug application (sNDA) is
expected by September 13, 2008. FENTORA is currently indicated for the
management of breakthrough pain in opioid-tolerant patients with cancer.
"We are disappointed with the recommendation of the Advisory
Committee," said Dr. Lesley Russell, Executive Vice President, Worldwide
Medical and Regulatory Operations at Cephalon. "We will work with the FDA
over the next few months to determine future steps including any additional
risk minimization strategies that could potentially address the panel's
concerns in this broader patient population."
The recommendation of the Joint Advisory Committee for Anesthetic and
Life Support Drugs and the Advisory Committee for Drug Safety and Risk
Management was based upon data presented by Cephalon from three randomized
clinical trials and one 18-month open-label safety study with a total of
941 patients. The Joint Advisory Committee also considered proposed
enhancements to the FENTORA RiskMAP that are designed to assure appropriate
patient selection and to mitigate the risks of overdose, abuse, and
diversion.
The FDA considers the Committee's recommendation in its review of the
sNDA for FENTORA, which was submitted by Cephalon in November 2007. The FDA
is not required to follow the Committee's guidance, but the agency does
take this advice into consideration when reviewing a proposed label
expansion.
Conference Call for Investors
Cephalon management will discuss the FDA Advisory Committee proceedings
with investors during a conference call beginning at 5:30 p.m. EDT today.
To participate in the conference call, dial 1-913-312-0407 and refer to
conference call ID number 2046179. Individual investors are encouraged to
log onto the investor relations section of http://www.cephalon.com and
click on the webcast to access the live call.
PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE
IMPORTANT WARNINGS IN THIS LABEL.
Reports of serious adverse events, including deaths in patients treated
with FENTORA have been reported. Deaths occurred as a result of improper
patient selection (e.g., use in opioid non-tolerant patients) and/or
improper dosing. The substitution of FENTORA for any other fentanyl product
may result in fatal overdose.
FENTORA is indicated only for the management of breakthrough pain in
patients with cancer who are already receiving and who are tolerant to
around-the-clock opioid therapy for their underlying persistent cancer
pain. Patients considered opioid tolerant are those who are taking
around-the-clock medicine consisting of at least 60 mg of oral morphine
daily, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of
oxycodone daily, at least 8 mg of oral hydromorphone daily, or an
equianalgesic dose of another opioid daily for a week or longer.
FENTORA is not indicated for use in opioid non-tolerant patients
including those with only as needed (PRN) prior exposure.
FENTORA is contraindicated in the management of acute or postoperative
pain including headache/migraine. Life-threatening respiratory depression
could occur at any dose in opioid non-tolerant patients. Deaths have
occurred in opioid non-tolerant patients.
When prescribing, do not convert patients on a mcg per mcg basis from
ACTIQ to FENTORA. Carefully consult the Initial Dosing Recommendations
table. (See DOSAGE AND ADMINISTRATION, Table 7.)
When dispensing, do not substitute a FENTORA prescription for other
fentanyl products. Substantial differences exist in the pharmacokinetic
profile of FENTORA compared to other fentanyl products that result in
clinically important differences in the extent of absorption of fentanyl.
As a result of these differences, the substitution of FENTORA for any other
fentanyl product may result in fatal overdose.
Special care must be used when dosing FENTORA. If the breakthrough pain
episode is not relieved after 30 minutes, patients may take ONLY one
additional dose using the same strength and must wait at least 4 hours
before taking another dose.(See DOSAGE AND ADMINISTRATION.)
FENTORA contains fentanyl, an opioid agonist and a Schedule II
controlled substance, with an abuse liability similar to other opioid
analgesics. FENTORA can be abused in a manner similar to other opioid
agonists, legal or illicit. This should be considered when prescribing or
dispensing FENTORA in situations where the physician or pharmacist is
concerned about an increased risk of misuse, abuse or diversion. Schedule
II opioid substances which include morphine, oxycodone, hydromorphone,
oxymorphone, and methadone have the highest potential for abuse and risk of
fatal overdose due to respiratory depression.
The concomitant use of FENTORA with strong and moderate cytochrome P450
3A4 inhibitors may result in an increase in fentanyl plasma concentrations,
and may cause potentially fatal respiratory depression.
Carefully consult the Initial Dosing Recommendations table. (See DOSAGE
AND ADMINISTRATION, Table 7.)
When dispensing, do not substitute a FENTORA prescription for other
fentanyl products. Substantial differences exist in the pharmacokinetic
profile of FENTORA compared to other fentanyl products that result in
clinically important differences in the extent of absorption of fentanyl.
As a result of these differences, the substitution of FENTORA for any other
fentanyl product may result in fatal overdose.
Special care must be used when dosing FENTORA. If the breakthrough pain
episode is not relieved after 30 minutes, patients may take ONLY one
additional dose using the same strength and must wait at least 4 hours
before taking another dose.(See DOSAGE AND ADMINISTRATION.)
For full prescribing information, including black box warning, visit
http://www.fentora.com, or call Cephalon Medical Services at
1-800-896-5855.
Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical
company dedicated to the discovery, development and commercialization of
innovative products in four core therapeutic areas: central nervous system,
pain, oncology and addiction. A member of the Fortune 1000, Cephalon
currently employs approximately 3,000 people in the United States and
Europe. U.S. sites include the company's headquarters in Frazer,
Pennsylvania, and offices, laboratories or manufacturing facilities in West
Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis,
Minnesota. The company's European headquarters are located in
Maisons-Alfort, France.
The company's proprietary products in the United States include:
TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R)
(cyclobenzaprine hydrochloride extended-release capsules), PROVIGIL(R)
(modafinil) Tablets [C-IV], FENTORA, TRISENOX(R) (arsenic trioxide)
injection, VIVITROL(R) (naltrexone for extended-release injectable
suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM)
(armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl
citrate) [C-II]. The company also markets numerous products
internationally. Full prescribing information on its U.S. products is
available at http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition,
this press release may contain forward-looking statements. Forward-looking
statements provide Cephalon's current expectations or forecasts of future
events. These may include statements regarding anticipated scientific
progress on its research programs; development of potential pharmaceutical
products; interpretation of clinical results, including the results of the
FENTORA clinical trials; prospects for final regulatory approval of
FENTORA, including the impact of the advisory committee's recommendation on
the FDA's decision whether to approve the sNDA for FENTORA; manufacturing
development and capabilities; market prospects for its products,
particularly with respect to FENTORA sales and earnings guidance; and other
statements regarding matters that are not historical facts.
You may identify some of these forward-looking statements by the use of
words in the statements such as "anticipate," "estimate," "expect,"
"project," "intend," "plan," "believe" or other words and terms of similar
meaning. Cephalon's performance and financial results could differ
materially from those reflected in these forward-looking statements due to
general financial, economic, regulatory and political conditions affecting
the biotechnology and pharmaceutical industries as well as more specific
risks and uncertainties facing Cephalon such as those set forth in its
reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect. Therefore, you
should not rely on any such factors or forward-looking statements.
Furthermore, Cephalon does not intend to update publicly any
forward-looking statement, except as required by law. The Private
Securities Litigation Reform Act of 1995 permits this discussion.
SOURCE Cephalon, Inc.
 back to top
Related links:
http://www.cephalon.com
http://www.prnewswire.com/comp/134563.html /
CONTACT:
Media, Candace Steele, work, +1-610-727-6231,
cell, +1-443-326-0077, csteele@cephalon.com; or Investors, Robert
(Chip) Merritt, +1-610-738-6376, cmerritt@cephalon.com, both of
Cephalon, Inc.
|
